The global glycosylated hemoglobin and c peptide market is anticipated to grow at a considerable CAGR during the forecast period. Pharmaceutical companies are working on developing effective drugs which are helpful in the treatment of chronic disorders such as diabetes. No of patients with chronic ailments are increasing in all regions of the world. As per the WHO, 422 million people worldwide have diabetes, the majority living in low-and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes.
Browse the full report description of “Global Glycosylated Hemoglobin And C Peptide Market Size, Share & Trends Analysis Report By Product (Tablet, Capsules, Injectable, and Others), By Application (Oncology, Blood Disorder, Diabetes, and Other) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/glycosylated-hemoglobin-and-c-peptide-market
Due to increasing diabetic prevalence which in turn increasing high demand for glycosylated hemoglobin and c peptide, the companies are joining hands with other biopharma companies for funding sources, operations, and commercialization purposes. Moreover, trials and studies are going on to know how glycosylated hemoglobin which is a marker for sugar in the body, can be maintained to keep the body balanced in chronic ailments. For instance, in Sept 2021, LeaderMed health group and Opko Health Inc. have announced a joint venture to develop and market Oxyntomodulin, which will be useful both in diabetes and obesity. Oxyntomodulin is a naturally produced hormone that is present in the colon part of the body. It together binds the GLP 1 and glucagon receptors which in turn helps in regulating blood glucose appetite and lipid metabolism.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Pfizer Inc., Medtronic, F.Hoffmann-La Roche Ltd., Sandoz International GmBh, Biocon Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Glycosylated Hemoglobin and C Peptide Market by Segment
By Product
By Application
Global Glycosylated Hemoglobin and C Peptide Market by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/glycosylated-hemoglobin-and-c-peptide-market